<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03180827</url>
  </required_header>
  <id_info>
    <org_study_id>PB_2017-00536 (15-073)</org_study_id>
    <nct_id>NCT03180827</nct_id>
  </id_info>
  <brief_title>Female Fertility Preservation Using Ovarian Tissue Cryopreservation Before Highly Gonadotoxic Cancer Treatment</brief_title>
  <official_title>Female Fertility Preservation Using Ovarian Tissue Cryopreservation Before Highly Gonadotoxic Cancer Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gumy-Pause Fabienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Due to the remarkable improvement in treatments these last decades, long term survival can be&#xD;
      expected in more than 80% of childhood cancer patients. Unfortunately, cancer treatments can&#xD;
      be harmful to the gonads and can affect reproductive and endocrine functions. While loss of&#xD;
      fertility is a major concern for most patients, only the experimental option of ovarian&#xD;
      tissue cryopreservation can be proposed to prepubertal girls with a high risk of infertility.&#xD;
      For pubertal patient, cryopreservation of mature oocytes after ovarian stimulation can be&#xD;
      offered if oncological treatment debut can be delayed. As it is often not possible, ovarian&#xD;
      tissue cryopreservation can also be offered.&#xD;
&#xD;
      Primary aims&#xD;
&#xD;
      - To cryopreserve ovarian tissue of pre or peripubertal patient who will be receiving highly&#xD;
      gonadotoxic oncological treatment.&#xD;
&#xD;
      Secondary aims&#xD;
&#xD;
        -  To create a database in order to record clinical and biological follow-up data&#xD;
&#xD;
        -  To pool resources with Fertisave Registry&#xD;
&#xD;
        -  To create a research biobank for future research projects&#xD;
&#xD;
      Multicentric study: HUG, CHUV&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Anticipated">January 2100</completion_date>
  <primary_completion_date type="Anticipated">January 2100</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of pediatric cancer patient who will undergo ovarian tissue cryopreservation for fertility preservation</measure>
    <time_frame>0-20 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of complications related to the ovarian biopsy (safety)</measure>
    <time_frame>0-20 years</time_frame>
    <description>The safety will be assessed by recording the number of complications of the procedure (e.g. bleeding, infection)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of biochemical markers</measure>
    <time_frame>0-20 years</time_frame>
    <description>Comparison of biochemical markers (e.g., FSH; LH, AMH, progesterone, oestradiol) between patients who undergo ovarian biopsy and controls</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Childhood Cancer</condition>
  <condition>Fertility Disorders</condition>
  <arm_group>
    <arm_group_label>ovarian tissue cryopreservation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ovarian tissue biopsy</intervention_name>
    <description>ovarian tissue biopsy during general anesthesia</description>
    <arm_group_label>ovarian tissue cryopreservation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric pre ou peripubertal patient aged 2 months and older&#xD;
&#xD;
          -  Patient presenting high risk of infertility because of gonadotoxic treatments (i.e.&#xD;
             high dose of alkylating agents, ovarian irradiation, total body irradiation)&#xD;
&#xD;
          -  Multidisciplinary team consensus in favour to proposition to cryopreserve ovarian&#xD;
             tissue.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under the age of 2 months&#xD;
&#xD;
          -  Refusal of the patient and/or her parents&#xD;
&#xD;
          -  Treatments that are not highly gonadotoxic&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fabienne Gumy-Pause, Dr</last_name>
    <email>fabienne.gumypause@hcuge.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Geneva University Hospitals</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabienne Gumy-Pause, Dr</last_name>
      <email>fabienne.gumypause@hcuge.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUV</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maja Beck Popovic, Prof</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 31, 2017</study_first_submitted>
  <study_first_submitted_qc>June 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Gumy-Pause Fabienne</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

